Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8,954 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
AKT isoform-specific expression and activation across cancer lineages.
Wang J, Zhao W, Guo H, Fang Y, Stockman SE, Bai S, Ng PK, Li Y, Yu Q, Lu Y, Jeong KJ, Chen X, Gao M, Liang J, Li W, Tian X, Jonasch E, Mills GB, Ding Z. Wang J, et al. Among authors: gao m. BMC Cancer. 2018 Jul 16;18(1):742. doi: 10.1186/s12885-018-4654-5. BMC Cancer. 2018. PMID: 30012111 Free PMC article.
COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms.
Lindemann A, Patel AA, Silver NL, Tang L, Liu Z, Wang L, Tanaka N, Rao X, Takahashi H, Maduka NK, Zhao M, Chen TC, Liu W, Gao M, Wang J, Frank SJ, Hittelman WN, Mills GB, Myers JN, Osman AA. Lindemann A, et al. Among authors: gao m. Clin Cancer Res. 2019 Sep 15;25(18):5650-5662. doi: 10.1158/1078-0432.CCR-19-0096. Epub 2019 Jul 15. Clin Cancer Res. 2019. PMID: 31308060 Free PMC article.
Verteporfin Inhibits PD-L1 through Autophagy and the STAT1-IRF1-TRIM28 Signaling Axis, Exerting Antitumor Efficacy.
Liang J, Wang L, Wang C, Shen J, Su B, Marisetty AL, Fang D, Kassab C, Jeong KJ, Zhao W, Lu Y, Jain AK, Zhou Z, Liang H, Sun SC, Lu C, Xu ZX, Yu Q, Shao S, Chen X, Gao M, Claret FX, Ding Z, Chen J, Chen P, Barton MC, Peng G, Mills GB, Heimberger AB. Liang J, et al. Among authors: gao m. Cancer Immunol Res. 2020 Jul;8(7):952-965. doi: 10.1158/2326-6066.CIR-19-0159. Epub 2020 Apr 7. Cancer Immunol Res. 2020. PMID: 32265228 Free PMC article.
Hormonal modulation of ESR1 mutant metastasis.
Gu G, Tian L, Herzog SK, Rechoum Y, Gelsomino L, Gao M, Du L, Kim JA, Dustin D, Lo HC, Beyer AR, Edwards DG, Gonzalez T, Tsimelzon A, Huang HJ, Fernandez NM, Grimm SL, Hilsenbeck SG, Liu D, Xu J, Alaniz A, Li S, Mills GB, Janku F, Kittler R, Zhang XH, Coarfa C, Foulds CE, Symmans WF, Andò S, Fuqua SAW. Gu G, et al. Among authors: gao m. Oncogene. 2021 Feb;40(5):997-1011. doi: 10.1038/s41388-020-01563-x. Epub 2020 Dec 15. Oncogene. 2021. PMID: 33323970 Free PMC article.
Correction to: Hormonal modulation of ESR1 mutant metastasis.
Gu G, Tian L, Herzog SK, Rechoum Y, Gelsomino L, Gao M, Du L, Kim JA, Dustin D, Lo HC, Beyer AR, Edwards DG, Gonzalez T, Tsimelzon A, Huang HJ, Fernandez NM, Grimm SL, Hilsenbeck SG, Liu D, Xu J, Alaniz A, Li S, Mills GB, Janku F, Kittler R, Zhang XH, Coarfa C, Foulds CE, Symmans WF, Andò S, Fuqua SAW. Gu G, et al. Among authors: gao m. Oncogene. 2022 Jan;41(3):460. doi: 10.1038/s41388-021-02104-w. Oncogene. 2022. PMID: 34782721 No abstract available.
Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function.
Kumar M, Molkentine D, Molkentine J, Bridges K, Xie T, Yang L, Hefner A, Gao M, Bahri R, Dhawan A, Frederick MJ, Seth S, Abdelhakiem M, Beadle BM, Johnson F, Wang J, Shen L, Heffernan T, Sheth A, Ferris RL, Myers JN, Pickering CR, Skinner HD. Kumar M, et al. Among authors: gao m. Nat Commun. 2021 Nov 3;12(1):6340. doi: 10.1038/s41467-021-26570-8. Nat Commun. 2021. PMID: 34732714 Free PMC article.
Variations in HPV function are associated with survival in squamous cell carcinoma.
Gleber-Netto FO, Rao X, Guo T, Xi Y, Gao M, Shen L, Erikson K, Kalu NN, Ren S, Xu G, Fisch KM, Akagi K, Seiwert T, Gillison M, Frederick MJ, Johnson FM, Wang J, Myers JN, Califano J, Skinner HD, Pickering CR. Gleber-Netto FO, et al. Among authors: gao m. JCI Insight. 2019 Jan 10;4(1):e124762. doi: 10.1172/jci.insight.124762. JCI Insight. 2019. PMID: 30626753 Free PMC article.
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation.
Piha-Paul SA, Tseng C, Tran HT, Gao M, Karp DD, Subbiah V, Tsimberidou AM, Kawedia JD, Fu S, Pant S, Yap TA, Morris VK, Kee BK, Blum Murphy M, Lim J, Meric-Bernstam F. Piha-Paul SA, et al. Among authors: gao m. Cancer Chemother Pharmacol. 2023 Aug;92(2):107-118. doi: 10.1007/s00280-023-04545-4. Epub 2023 Jun 14. Cancer Chemother Pharmacol. 2023. PMID: 37314501 Free PMC article. Clinical Trial.
8,954 results